← Back to Search

Cytokine

GCSF for Infertility

Phase 4

Recruiting

Led By Samuel Soliman, M.D.

Research Sponsored by Newlife Fertility Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment to the time of birth (up to 9-months post-et).

Awards & highlights

Drug Has Already Been Approved

Pivotal Trial

Summary

This trial seeks to see if adding GCSF to embryo transfer media can improve IVF success rates.

Who is the study for?

This trial is for women with unexplained infertility who are undergoing in vitro fertilization (IVF). It includes those having fresh embryo transfers or frozen embryo transfers. Women with uterine issues, severe male factor infertility, or multiple IVF failures cannot participate.

What is being tested?

The study tests if adding Granulocyte Colony-Stimulating Factor (G-CSF) to the standard embryo transfer media improves IVF outcomes like implantation and pregnancy rates. Participants will be randomly assigned to receive either the G-CSF supplemented media or the standard one during their transfer.

What are the potential side effects?

While not explicitly stated here, potential side effects of G-CSF may include bone pain, headache, nausea, and redness at injection site. However, since it's added to transfer media and not injected directly into participants these specific side effects might differ.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from enrollment to the time of birth (up to 9-months post-et).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from enrollment to the time of birth (up to 9-months post-et).

This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to the time of birth (up to 9-months post-et). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Clinical Pregnancy Rate

Implantation Rate

Live Birth Rate

+1 more

Secondary study objectives

Biochemical Pregnancy Rate

Spontaneous Abortion Rate

Side effects data

From 2014 Phase 3 trial • 118 Patients • NCT00003138

31%

Fatigue

23%

Pulmonary

15%

Infection

Cardiac adverse event

Diarrhea

Esophagitis

Hot flashes

Other toxicities

Hemorrhage

Skin

Weight loss

Neuropathy-clinical

Edema

Anemia

Neuropathy-psych

Abdominal cramps

100%

80%

60%

40%

20%

Study treatment Arm

Erythropoietin (300 Units/kg) and Filgrastim (Step 4)

Supportive Care (Step 1)

Erythropoietin (Step 1)

Erythropoietin (Cross-over; Step 2)

Erythropoietin (150 Units/kg) and Filgrastim (Step 3)

Awards & Highlights

Drug Has Already Been Approved

The FDA has already approved this drug, and is just seeking more data.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: GCSF-Supplemented Embryo Transfer MediaExperimental Treatment1 Intervention

Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician. Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.

Group II: Standard Embryo Transfer MediaPlacebo Group1 Intervention

Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician. Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.

Do I qualify?Apply below to find out